Skip to content
‹ Back to IndustriesHealthcare

DESIGN TRANSFER: A PROCESS NOT A SINGULAR EVENT

In the development process for medical devices, there comes a point when products transfer from design to production. Often this step doesn’t go as smoothly as it should and the project budget and schedule are adversely impacted. Companies may view design transfer as a one-time event, rather than an essential part of an ongoing process….

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

·
Share

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

In the development process for medical devices, there comes a point when products transfer from design to production. Often this step doesn’t go as smoothly as it should and the project budget and schedule are adversely impacted. Companies may view design transfer as a one-time event, rather than an essential part of an ongoing process.

During the product development process, the Research and Development (R&D) team is under a tight deadline. They may not have the necessary resources or take sufficient time to create proper documentation. Team members may need to make decisions quickly without fully considering how they could take proactive steps to ensure design transfer will go more smoothly. Subject matter experts on the team may only focus on critical design decisions required to make the product work, without regard for manufacturing. Let’s take a look at some ways to improve design transfer.

Look at Design Transfer as a Process Rather than a Single Event

Design transfer is an integral part of the product development process, from conception through final manufacture. Highly reliable, cost-efficient medical devices require proper design transfer, and that starts with Design for Manufacturability (DFM) and Design for Manufacturing and Assembly (DFMA). In DFM and DFMA the focus is not only on the design itself, but also on the assembly method, ensuring manufacturing readiness for building Beta units, pre-production clinical units, and the pilot program. When the R&D team considers these factors and performs in-process testing, it can significantly improve product quality and reduce the overall cost of manufacturing.

Using DFMA 

The goal of DFMA is simple: to transfer product design into viable, robust production methods. To succeed, the team must establish and maintain procedures that ensure the device design translates into production specifications, including final test acceptance. The transfer should negate and/or identify remaining risks such as single-sourcing, long lead items, build timelines, and line/tooling capacity.

A Design Ready for Transfer:

  • Can be built reliably using known and proven manufacturing and assembly processes
  • Includes supporting cell/line qualifications through manufacturing validations such as Operational Qualification (OQ) and Performance Qualification (PQ)
  • Specifies and documents any inspection aids, assembly fixtures, and custom tools required for manufacture
  • Confirms completed agency testing and production target hardware meets regulatory requirements such as FDA, UL, and CE
  • Includes a complete product Bill of Material (BOM) that has been fully costed up to the customer Stock Keeping Unit (SKU) level
  • Includes packaging, labeling, and Instructions for Use (IFU)

At Sunrise Labs, we see Design Transfer as an integral process beginning early in the life of a product with many crucial steps for success. Communication between key stakeholders early and often is critical to turn innovative ideas into commercial medical devices.

Read more at sunriselabs.com

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

New York City digital health startups raised $1.9 billion in Q3, up 36%

New York City digital health startups raised $1.9 billion in Q3, up 36%

New York City digital health startups raised $1.9 billion in Q3 2026, up 36% year over year. Nationally, Rock Health counted $3.7 billion raised by U.S. digital health startups across 114 deals in the quarter. Bigger checks and steady acquisitions mean buyers must assess which vendors are pulling ahead—and which may change owners mid-rollout.

  • 01New York's digital health startups grew Q3 funding 36% year over year, while U.S. digital health startups raised $3.7 billion across 114 deals in Q3, according to Rock Health.
  • 02Average U.S. digital health deal size has climbed from $20.6 million in 2024 to $31.0 million so far in 2026, so more of the money is going into bigger rounds.
  • 03Acquisition is still how most digital health companies exit, with 164 deals through Q3 2026 and no new public listings since August 2025. That makes a vendor's change-of-ownership terms a live contract question for buyers.

Nov 4, 2026

LeanTaaS buys LookDeep Health and brings computer vision into hospital patient rooms

LeanTaaS buys LookDeep Health and brings computer vision into hospital patient rooms

LeanTaaS said on November 3 it acquired LookDeep Health, a computer vision company, and introduced iQueue for Virtual Care, its first product built on what it calls ambient intelligence. Terms were not disclosed. The product bundles Virtual Observation, Virtual Nursing and Virtual Medicine, and LeanTaaS says hospitals can build on compatible cameras and in-room devices already installed or deploy supported hardware. The company cited reported results from LookDeep deployments, including fall-rate reductions of more than 70%, and said LookDeep's technology was evaluated in peer-reviewed research published in Frontiers in Imaging.

  • 01LeanTaaS acquired LookDeep Health and launched iQueue for Virtual Care, combining Virtual Observation, Virtual Nursing and Virtual Medicine; acquisition terms were not disclosed.
  • 02Hospitals can build on compatible cameras and in-room devices already in place or deploy supported hardware, according to LeanTaaS, which did not name camera vendors.
  • 03LeanTaaS reported results from LookDeep deployments including fall-rate reductions of more than 70% and twice as much nursing contact, figures that are the company's own and not tied to named health systems.

Nov 3, 2026

Philips posts 8% order intake growth in Q3 and books a EUR 288 million Respironics provision

Philips posts 8% order intake growth in Q3 and books a EUR 288 million Respironics provision

Royal Philips reported 8% comparable order intake growth for the third quarter of 2026, driven by Diagnosis & Treatment, with comparable sales up 3% to EUR 4.4 billion and an adjusted EBITA margin of 13.0%, up 70 basis points. The company reiterated its 2026 outlook for 3% to 4.5% comparable sales growth. Philips Respironics reached an agreement in principle with the US Department of Justice to resolve previously disclosed investigations related to its recall, and Philips recorded a EUR 288 million provision in the quarter, with payment expected in the first quarter of 2027 subject to final documentation.

  • 01Comparable order intake grew 8%, matching a year earlier, with Diagnosis & Treatment the driver; the equipment order book stands at about 40% of revenue.
  • 02Comparable sales rose 3% to EUR 4.4 billion, adjusted EBITA margin reached 13.0%, and free cash flow was EUR 384 million; the 2026 outlook was reiterated.
  • 03Philips Respironics reached an agreement in principle with the DOJ on previously disclosed recall investigations, and Philips recorded a EUR 288 million provision; the settlement is subject to final documentation.

Nov 3, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512